# Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac

> **NCT05947461** · NA · TERMINATED · sponsor: **Air Force Military Medical University, China** · enrollment: 1204 (actual)

## Conditions studied

- Post-ERCP Acute Pancreatitis
- NSAIDs
- Indomethacin
- Diclofenac
- Endoscopic Retrograde Cholangiopancreatography

## Interventions

- **DRUG:** 100mg diclofenac
- **DRUG:** 100mg indomethacin

## Key facts

- **NCT ID:** NCT05947461
- **Lead sponsor:** Air Force Military Medical University, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-01
- **Primary completion:** 2024-06-22
- **Final completion:** 2024-06-22
- **Target enrollment:** 1204 (ACTUAL)
- **Why stopped:** The data from the interim analysis showed a opposite trend predicting possible of benefit of indomethacin and conditional power analysis revealed a low probability of confirming the benefit of diclofenac if this trial will be continued.
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947461, "Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05947461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*